Cipla (CIPLA)₹1,404−0.14%Pharmaceuticals
In the Sep 2026 quarter (consolidated), Cipla reported sales of ₹7,426 Cr, down 2.5% from Sep 2025, and net profit of ₹854 Cr, down 37.1% year on year. For the year to Mar 2026, sales were ₹28,258 Cr and net profit ₹3,871 Cr.
Company filings, consolidated accounts; latest reported quarter Sep 2026
| Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 6,625 | 6,189 | 6,721 | 7,079 | 7,096 | 6,759 | 6,986 | 7,614 | 7,100 | 6,563 | 7,145 | 7,426 |
| Expenses | 4,855 | 4,841 | 4,973 | 5,166 | 5,080 | 5,185 | 5,178 | 5,691 | 5,820 | 5,587 | 5,922 | 6,013 |
| Operating Profit | 1,756 | 1,321 | 1,723 | 1,893 | 1,995 | 1,545 | 1,785 | 1,901 | 1,259 | 959 | 1,196 | 1,394 |
| OPM % | 26.0% | 20.9% | 25.9% | 26.9% | 28.0% | 22.9% | 25.9% | 25.0% | 18.0% | 15.0% | 16.9% | 18.9% |
| Other Income | −9.99 | 249 | 160 | 191 | 222 | 289 | 259 | 269 | −70.04 | 148 | 211 | 151 |
| Interest | 30.01 | 18.01 | 17.99 | 14.99 | 15.01 | 14.01 | 13.98 | 12.98 | 13.99 | 12.99 | 16.99 | 17.01 |
| Depreciation | 232 | 287 | 246 | 271 | 279 | 308 | 252 | 296 | 277 | 382 | 303 | 344 |
| Profit before tax | 1,480 | 1,263 | 1,616 | 1,796 | 1,923 | 1,510 | 1,777 | 1,860 | 896 | 709 | 1,085 | 1,182 |
| Tax % | 28.1% | 26.1% | 27.1% | 27.1% | 17.1% | 19.1% | 27.1% | 27.1% | 24.1% | 22.1% | 27.1% | 27.0% |
| Exceptional items | −141 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | −209 | 0.00 | 0.00 | 0.00 |
| Net Profit | 1,072 | 935 | 1,178 | 1,308 | 1,581 | 1,218 | 1,296 | 1,357 | 676 | 544 | 788 | 854 |
| EPS (Rs) | 13.04 | 11.61 | 14.55 | 16.09 | 19.40 | 15.09 | 16.01 | 16.69 | 8.35 | 6.85 | 9.74 | 10.83 |
| Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 13,847 | 14,441 | 15,221 | 16,433 | 17,187 | 19,234 | 21,843 | 22,821 | 25,883 | 27,666 | 28,258 | 28,233 |
| Expenses | 11,306 | 11,888 | 12,314 | 13,265 | 13,913 | 14,909 | 17,196 | 17,717 | 19,459 | 20,394 | 22,285 | 23,342 |
| Operating Profit | 2,491 | 2,504 | 2,837 | 3,111 | 3,218 | 4,268 | 4,567 | 5,042 | 6,315 | 7,160 | 5,907 | 4,808 |
| OPM % | 17.9% | 16.9% | 19.0% | 18.9% | 18.9% | 21.9% | 20.9% | 21.9% | 23.9% | 25.9% | 21.0% | 17.0% |
| Other Income | 208 | 208 | 280 | 477 | 344 | 266 | 99.10 | 293 | 552 | 862 | 606 | 440 |
| Interest | 207 | 159 | 114 | 168 | 197 | 161 | 106 | 110 | 90.01 | 62.01 | 53.98 | 60.98 |
| Depreciation | 752 | 1,320 | 1,319 | 1,321 | 1,171 | 1,066 | 1,049 | 1,169 | 1,048 | 1,105 | 1,207 | 1,306 |
| Profit before tax | 1,733 | 1,226 | 1,675 | 2,085 | 2,186 | 3,303 | 3,506 | 4,053 | 5,721 | 6,847 | 5,240 | 3,872 |
| Tax % | 19.1% | 15.1% | 15.1% | 27.1% | 29.1% | 27.1% | 27.1% | 30.1% | 27.1% | 22.1% | 26.1% | — |
| Exceptional items | 48.12 | 96.33 | 64.16 | 121 | 88.24 | 35.09 | −65.15 | −40.12 | −86.19 | 127 | 73.24 | −209 |
| Net Profit | 1,387 | 1,038 | 1,420 | 1,495 | 1,505 | 2,397 | 2,554 | 2,839 | 4,168 | 5,285 | 3,871 | 2,862 |
| EPS (Rs) | 16.88 | 12.47 | 17.47 | 18.90 | 19.13 | 29.76 | 31.08 | 34.59 | 50.94 | 65.13 | 47.88 | 35.77 |
| Dividend payout % | 12.0% | 16.0% | 17.0% | 16.0% | 21.0% | 17.0% | 15.9% | 24.0% | 25.0% | 25.0% | 27.0% | — |
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 161 | 161 | 161 | 161 | 161 | 161 | 161 | 161 | 161 | 161 | 162 | 162 |
| Reserves | 10,648 | 11,355 | 12,399 | 14,072 | 14,847 | 15,607 | 18,179 | 20,704 | 23,262 | 26,563 | 31,043 | 34,273 |
| Borrowings | 1,706 | 5,209 | 4,123 | 4,102 | 4,321 | 2,820 | 2,018 | 1,058 | 804 | 560 | 439 | 615 |
| Other Liabilities | 3,181 | 4,352 | 4,233 | 4,367 | 4,454 | 4,866 | 4,536 | 4,984 | 5,113 | 5,292 | 5,729 | 7,332 |
| Total Liabilities | 15,696 | 21,077 | 20,916 | 22,703 | 23,784 | 23,456 | 24,895 | 26,907 | 29,342 | 32,578 | 37,373 | 42,382 |
| Fixed Assets | 6,853 | 9,396 | 9,528 | 9,984 | 9,639 | 9,717 | 9,556 | 9,723 | 9,195 | 9,649 | 10,045 | 12,484 |
| CWIP | 582 | 2,065 | 1,687 | 982 | 678 | 827 | 972 | 768 | 1,096 | 1,156 | 1,569 | 2,047 |
| Investments | 639 | 757 | 970 | 1,255 | 2,546 | 1,468 | 2,703 | 2,545 | 3,653 | 5,435 | 7,909 | 8,198 |
| Other Assets | 7,624 | 8,860 | 8,730 | 10,481 | 10,921 | 11,444 | 11,665 | 13,872 | 15,396 | 16,338 | 17,849 | 19,652 |
| Inventories | 3,786 | 3,815 | 3,492 | 4,050 | 3,969 | 4,385 | 4,677 | 5,358 | 5,162 | 5,244 | 5,646 | 6,609 |
| Trade receivables | 1,995 | 2,352 | 2,556 | 3,096 | 4,142 | 3,881 | 3,438 | 3,417 | 4,051 | 4,758 | 5,496 | 5,611 |
| Cash & equivalents | 564 | 870 | 624 | 965 | 618 | 1,003 | 1,399 | 1,928 | 1,564 | 874 | 799 | 1,306 |
| Total Assets | 15,696 | 21,077 | 20,916 | 22,703 | 23,784 | 23,456 | 24,895 | 26,907 | 29,342 | 32,578 | 37,373 | 42,382 |
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operating activity | 1,170 | 1,735 | 2,373 | 1,458 | 1,686 | 3,059 | 3,746 | 3,319 | 3,229 | 4,118 | 4,988 | 3,927 |
| Cash from investing activity | −948 | −4,526 | −1,300 | −832 | −1,685 | 114 | −2,368 | −1,854 | −2,373 | −2,973 | −3,673 | −2,228 |
| Cash from financing activity | 165 | 3,113 | −1,331 | −386 | −350 | −2,956 | −1,243 | −1,606 | −961 | −1,204 | −1,296 | −1,238 |
| Net cash flow | 389 | 313 | −249 | 243 | −346 | 235 | 141 | −132 | −97.23 | −49.12 | 30.05 | 474 |
| Capex | 649 | 1,082 | 1,140 | 820 | 529 | 1,004 | 822 | 704 | 1,188 | 1,354 | 1,555 | 3,091 |
| Free cash flow | 546 | 685 | 1,280 | 720 | 1,182 | 2,075 | 2,955 | 2,636 | 2,094 | 2,810 | 3,480 | 925 |
| CFO / OP % | 72.0% | 90.9% | 113.0% | 77.0% | 74.0% | 122.0% | 113.0% | 97.9% | 90.0% | 90.9% | 94.0% | 93.9% |
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor days | 64 | 62 | 65 | 75 | 93 | 83 | 66 | 57 | 65 | 68 | 73 | 73 |
| Inventory days | 328 | 272 | 238 | 270 | 249 | 266 | 231 | 229 | 227 | 216 | 230 | 251 |
| Days payable | 127 | 107 | 109 | 143 | 124 | 140 | 104 | 109 | 113 | 103 | 117 | 124 |
| Cash conversion cycle | 266 | 229 | 195 | 203 | 219 | 210 | 194 | 179 | 180 | 181 | 187 | 201 |
| Working capital days | 88 | −11 | 98 | 117 | 131 | 112 | 93 | 94 | 112 | 119 | 127 | 105 |
| ROCE % | 15.0% | 13.0% | 7.0% | 9.0% | 11.1% | 12.1% | 17.1% | 17.0% | 18.1% | 23.1% | 23.1% | 15.0% |
For the Sep 2026 quarter, Cipla reported sales of ₹7,426 Cr, down 2.5% year on year and net profit of ₹854 Cr, down 37.1% year on year. The operating margin was 18.9%.
Cipla's sales for the year to Mar 2026 were ₹28,258 Cr; over the last twelve months they were ₹28,233 Cr.
Net profit for the year to Mar 2026 was ₹3,871 Cr, and ₹2,862 Cr over the last twelve months. Earnings per share over the same trailing period were ₹35.77.
Cipla reported borrowings of ₹615 Cr at Mar 2026, against cash and equivalents of ₹1,306 Cr.
Cash from operations was ₹3,927 Cr in the year to Mar 2026; after capital spending, free cash flow was ₹925 Cr.